Cytek Q4 revenue $48.3M (+24% YoY); guides FY2023 $225-235M (+37-43%)

Cytek Biosciences, Inc.

2022-FY EPS reported $0.02 revenue$164,036,000

Full-year 2022 revenue $164.0M, up 28% YoY (34% constant currency); net income $2.5M.
Q4 net income $3.7M vs loss $1.2M in Q4 2021; adjusted EBITDA $6.6M.
2023 revenue guidance $225-235M, including ~$20M from Luminex acquisition closed Feb 28.
Acquired Luminex's Flow Cytometry and Imaging business; partnership with Bio-Rad.
Cash and short-term investments $341.1M; 560 instrument placements in 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cytek Biosciences, Inc. reported full year 2023 results: revenue $225 million to $235 million. Guidance initiated.

Period: full year 2023
Revenue: $225 million to $235 million
Guidance: initiated
Result: guidance update

Exact text from the filing

Cytek Biosciences expects full year 2023 revenue in the range of $225 million to $235 million, representing growth of 37% to 43% over full year 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cytek Biosciences, Inc. reported the year ended December 31, 2022 results: revenue $164.0 million, net income $2.5 million.

Period: the year ended December 31, 2022
Revenue: $164.0 million
Net income: $2.5 million
Result: reported results

Exact text from the filing

Total revenue for the year ended December 31, 2022 was $164.0 million, a 28% increase over the year ended December 31, 2021. On a constant currency basis, total revenue for the full year 2022 was $171.8 million, a 34% increase over the full year 2021. Gross profit was $101.0 million for the year ended December 31, 2022, an increase of 28% compared to a gross profit of $79.1 million in the year ended December 31, 2021. Gross profit margin was 62% in the year ended December 31, 2022 compared to 62% in the year ended December 31, 2021. Adjusted gross profit margin in the year ended December 31, 2022 was 63% compared to 63% in the year ended December 31, 2021, after adjusting for stock-based compensation expense and amortization of acquisition-related intangibles. Operating expenses were $102.8 million for the year ended December 31, 2022, a 47% increase from $70.0 million in the year ended December 31, 2021. The increase was primarily due to expenses to support continued growth of the bus

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cytek Biosciences, Inc. reported the fourth quarter of 2022 results: revenue $48.3 million, net income $3.7 million.

Period: the fourth quarter of 2022
Revenue: $48.3 million
Net income: $3.7 million
Result: reported results

Exact text from the filing

Total revenue for the fourth quarter of 2022 was $48.3 million, a 24% increase over the fourth quarter of 2021, with continued demand across the full portfolio of Cytek’s offerings. On a constant currency basis, total revenue for the fourth quarter of 2022 was $51.2 million, a 32% increase over the fourth quarter of 2021. Gross profit was $29.4 million for the fourth quarter of 2022, an increase of 24% compared to a gross profit of $23.6 million in the fourth quarter of 2021. Gross profit margin was 61% in the fourth quarter of 2022 compared to 61% in the fourth quarter of 2021. Adjusted gross profit margin in the fourth quarter of 2022 was 62% compared to 63% in the fourth quarter of 2021, after adjusting for stock-based compensation expense and amortization of acquisition-related intangibles. Operating expenses were $29.3 million for the fourth quarter of 2022, a 31% increase from $22.3 million in the fourth quarter of 2021. The increase was primarily due to expenses to support conti

View on SEC.gov

Browse all earnings releases →

Cytek Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-053897

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.